Literature DB >> 27194529

The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission.

Mari Arai1, Makoto Naganuma2, Shinya Sugimoto1, Hiroki Kiyohara1, Keiko Ono1, Kiyoto Mori1, Keiichiro Saigusa1, Kosaku Nanki1, Makoto Mutaguchi1, Shinta Mizuno1, Rieko Bessho1, Yoshihiro Nakazato3, Naoki Hosoe3, Katsuyoshi Matsuoka1, Nagamu Inoue4, Haruhiko Ogata3, Yasushi Iwao4, Takanori Kanai1.   

Abstract

BACKGROUND: The ulcerative colitis endoscopic index of severity [UCEIS] is a validated scoring system. Nevertheless, few studies have investigated its usefulness in clinical settings. In this study, we aimed to predict the clinical prognosis of patients with ulcerative colitis [UC] in clinical remission using the UCEIS.
METHODS: A total of 285 UC patients who underwent a colonoscopy between April 2012 and March 2013 were enrolled. We reviewed clinical characteristics and endoscopic scores at the time of the colonoscopy and checked the clinical remission rate of the patients until September 2015. Clinical remission and recurrence were defined as a partial Mayo score of ≤1 and ≥3, respectively.
RESULTS: UCEIS was strongly correlated with the Mayo endoscopic score [r=0.93], moderately correlated with clinical severity [r=0.64] and mildly correlated with C-reactive protein [r=0.34]. The recurrence rate increased gradually as it became more endoscopically severe [5.0% for UCEIS=0, 22.4% for UCEIS=1, 27.0% for UCEIS=2, 35.7% for UCEIS=3 and 75.0% for UCEIS=4-5] in patients with clinical remission. UCEIS and the concomitant use of thiopurine were independent factors predicting clinical recurrence. A multivariate analysis indicated that the absence of bleeding [p≤0.001] and the absence of mucosal damage [p<0.001] in a colonoscopy were independent factors for prolongation of clinical remission.
CONCLUSION: The UCEIS is useful to predict the medium- to long-term outcomes of UC patients with clinical remission. The absence of bleeding or mucosal damage is important for maintaining clinical remission.
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  UCEIS; Ulcerative colitis; endoscopic indice; long-term prognosis

Mesh:

Substances:

Year:  2016        PMID: 27194529     DOI: 10.1093/ecco-jcc/jjw104

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  18 in total

1.  Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial.

Authors:  Makoto Naganuma; Yoko Yokoyama; Satoshi Motoya; Kenji Watanabe; Koji Sawada; Fumito Hirai; Takayuki Yamamoto; Hiroyuki Hanai; Teppei Omori; Takanori Kanai; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2019-12-06       Impact factor: 7.527

Review 2.  Recent trends and future directions for the medical treatment of ulcerative colitis.

Authors:  Makoto Naganuma; Shinta Mizuno; Kosaku Nanki; Shinya Sugimoto; Takanori Kanai
Journal:  Clin J Gastroenterol       Date:  2016-10-03

3.  Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.

Authors:  Parambir S Dulai; Siddharth Singh; Vipul Jairath; Christopher Ma; Neeraj Narula; Niels Vande Casteele; Laurent Peyrin-Biroulet; Severine Vermeire; Geert D'Haens; Brian G Feagan; William J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2019-11-22       Impact factor: 8.171

4.  Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.

Authors:  Makoto Naganuma; Shinya Sugimoto; Tomohiro Fukuda; Keiichi Mitsuyama; Taku Kobayashi; Naoki Yoshimura; Hidehisa Ohi; Shinji Tanaka; Akira Andoh; Naoki Ohmiya; Keiichiro Saigusa; Takayuki Yamamoto; Yuichi Morohoshi; Hitoshi Ichikawa; Katsuyoshi Matsuoka; Tadakazu Hisamatsu; Kenji Watanabe; Shinta Mizuno; Takayuki Abe; Yasuo Suzuki; Takanori Kanai
Journal:  J Gastroenterol       Date:  2019-09-16       Impact factor: 7.527

Review 5.  Endoscopic Surveillance in Inflammatory Bowel Disease.

Authors:  Martin Goetz
Journal:  Visc Med       Date:  2018-01-26

6.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

7.  Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.

Authors:  Makoto Naganuma; Nobuo Aoyama; Tomohiro Tada; Kiyonori Kobayashi; Fumihito Hirai; Kenji Watanabe; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2017-08-04       Impact factor: 7.527

8.  Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study.

Authors:  Satohiro Matsumoto; Haruna Kawamura; Takeshi Nishikawa; Noriyoshi Sagihara; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Clin Exp Gastroenterol       Date:  2017-09-26

9.  The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.

Authors:  Tomohiro Fukuda; Makoto Naganuma; Shinya Sugimoto; Kosaku Nanki; Shinta Mizuno; Makoto Mutaguchi; Yoshihiro Nakazato; Nagamu Inoue; Haruhiko Ogata; Yasushi Iwao; Takanori Kanai
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

10.  Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis.

Authors:  Dae Gon Ryu; Hyung Wook Kim; Su Bum Park; Dae Hwan Kang; Cheol Woong Choi; Su Jin Kim; Hyeong Seok Nam
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.